WEIGAO GROUP's revenue in the third quarter was approximately 3.26 billion yuan, a year-on-year increase of about 2.6%
I'm PortAI, I can summarize articles.
According to the announcement from WEIGAO GROUP, for the three months ending September 30, 2025, the company achieved unaudited revenue of approximately RMB 3.26 billion, an increase of about 2.6% compared to the same period last year. Among them, the orthopedics, interventional, and blood management segments experienced rapid revenue growth; however, the pharmaceutical packaging and general medical device segments were impacted by policy-related pressure on the sales prices of products such as syringe injectors, which dragged down the overall sales revenue growth of the group
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments